Vermillion, Inc. (NASDAQ:VRML) had its price target boosted by investment analysts at Canaccord Genuity from $1.75 to $2.25 in a note issued to investors on Thursday. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity’s price objective suggests a potential upside of 53.12% from the stock’s previous close.

Separately, ValuEngine cut shares of Vermillion from a “hold” rating to a “sell” rating in a report on Friday, July 28th.

Vermillion (NASDAQ:VRML) last issued its earnings results on Wednesday, August 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.04). Vermillion had a negative net margin of 372.05% and a negative return on equity of 215.26%. The firm had revenue of $0.90 million for the quarter.

WARNING: This piece of content was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/02/vermillion-inc-vrml-price-target-raised-to-2-25-at-canaccord-genuity.html.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Birchview Capital LP raised its holdings in shares of Vermillion by 7.9% during the third quarter. Birchview Capital LP now owns 2,462,933 shares of the company’s stock valued at $4,433,000 after buying an additional 180,000 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Vermillion by 0.7% during the second quarter. Vanguard Group Inc. now owns 580,484 shares of the company’s stock valued at $1,068,000 after buying an additional 4,200 shares during the last quarter. Finally, Essex Investment Management Co. LLC raised its holdings in shares of Vermillion by 145.8% during the third quarter. Essex Investment Management Co. LLC now owns 216,607 shares of the company’s stock valued at $390,000 after buying an additional 128,494 shares during the last quarter. 35.55% of the stock is currently owned by institutional investors.

About Vermillion

Vermillion, Inc is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery.

Receive News & Ratings for Vermillion Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion Inc. and related companies with MarketBeat.com's FREE daily email newsletter.